TBPH PE Ratio & Valuation,Is TBPH Overvalued

TBPH Relative Valuation

TBPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TBPH is overvalued; if below, it's undervalued.

Historical Valuation

Theravance Biopharma Inc (TBPH) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.27 is considered Undervalued compared with the five-year average of -53.26. The fair price of Theravance Biopharma Inc (TBPH) is between 34.91 to 50.51 according to relative valuation methord. Compared to the current price of 17.94 USD , Theravance Biopharma Inc is Undervalued By 48.61%.

Relative Value

Fair Zone

34.91-50.51

Current Price：17.94

48.61%

Undervalued

24.53

0.00

EV/EBITDA

Theravance Biopharma Inc. (TBPH) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -87.39. The thresholds are as follows: Strongly Undervalued below -827.52, Undervalued between -827.52 and -457.46, Fairly Valued between 282.67 and -457.46, Overvalued between 282.67 and 652.74, and Strongly Overvalued above 652.74. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

847.65

EV/EBIT

Theravance Biopharma Inc. (TBPH) has a current EV/EBIT of 847.65. The 5-year average EV/EBIT is 7.22. The thresholds are as follows: Strongly Undervalued below -244.14, Undervalued between -244.14 and -118.46, Fairly Valued between 132.90 and -118.46, Overvalued between 132.90 and 258.58, and Strongly Overvalued above 258.58. The current Forward EV/EBIT of 847.65 falls within the Strongly Overvalued range.

8.27

Theravance Biopharma Inc. (TBPH) has a current PS of 8.27. The 5-year average PS is 9.61. The thresholds are as follows: Strongly Undervalued below 0.62, Undervalued between 0.62 and 5.12, Fairly Valued between 14.11 and 5.12, Overvalued between 14.11 and 18.61, and Strongly Overvalued above 18.61. The current Forward PS of 8.27 falls within the Historic Trend Line -Fairly Valued range.

8.79

P/OCF

Theravance Biopharma Inc. (TBPH) has a current P/OCF of 8.79. The 5-year average P/OCF is -11.85. The thresholds are as follows: Strongly Undervalued below -99.13, Undervalued between -99.13 and -55.49, Fairly Valued between 31.80 and -55.49, Overvalued between 31.80 and 75.44, and Strongly Overvalued above 75.44. The current Forward P/OCF of 8.79 falls within the Historic Trend Line -Fairly Valued range.

-89.61

P/FCF

Theravance Biopharma Inc. (TBPH) has a current P/FCF of -89.61. The 5-year average P/FCF is -12.34. The thresholds are as follows: Strongly Undervalued below -104.94, Undervalued between -104.94 and -58.64, Fairly Valued between 33.96 and -58.64, Overvalued between 33.96 and 80.27, and Strongly Overvalued above 80.27. The current Forward P/FCF of -89.61 falls within the Undervalued range.

Theravance Biopharma Inc (TBPH) has a current Price-to-Book (P/B) ratio of 3.95. Compared to its 3-year average P/B ratio of 2.30 , the current P/B ratio is approximately 72.12% higher. Relative to its 5-year average P/B ratio of 0.48, the current P/B ratio is about 725.99% higher. Theravance Biopharma Inc (TBPH) has a Forward Free Cash Flow (FCF) yield of approximately 26.44%. Compared to its 3-year average FCF yield of -6.01%, the current FCF yield is approximately -540.32% lower. Relative to its 5-year average FCF yield of -13.87% , the current FCF yield is about -290.68% lower.

3.87

P/B

Median3y

2.30

Median5y

0.48

26.44

FCF Yield

Median3y

-6.01

Median5y

-13.87

Competitors Valuation Multiple

The average P/S ratio for TBPH's competitors is 0.58, providing a benchmark for relative valuation. Theravance Biopharma Inc Corp (TBPH) exhibits a P/S ratio of , which is -100% above the industry average. Given its robust revenue growth of 18.51%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of TBPH increased by 88.84% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 10.40 to 30.62.

The secondary factor is the Revenue Growth, contributed 18.51%to the performance.

Overall, the performance of TBPH in the past 1 year is driven by P/E Change. Which is more unsustainable.

18.51%

16.87M → 19.99M

Revenue Growth

-124.02%

-75.28 → 18.08

Margin Expansion

194.35%

10.40 → 30.62

P/E Change

88.84%

9.41 → 17.77

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Theravance Biopharma Inc (TBPH) currently overvalued or undervalued?

What is Theravance Biopharma Inc (TBPH) fair value?

TBPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Theravance Biopharma Inc (TBPH) is between 34.91 to 50.51 according to relative valuation methord.

How does TBPH's valuation metrics compare to the industry average?

The average P/S ratio for TBPH's competitors is 0.58, providing a benchmark for relative valuation. Theravance Biopharma Inc Corp (TBPH) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 18.51%, this premium appears unsustainable.

What is the current P/B ratio for Theravance Biopharma Inc (TBPH) as of Dec 16 2025?

As of Dec 16 2025, Theravance Biopharma Inc (TBPH) has a P/B ratio of 3.95. This indicates that the market values TBPH at 3.95 times its book value.

What is the current FCF Yield for Theravance Biopharma Inc (TBPH) as of Dec 16 2025?

As of Dec 16 2025, Theravance Biopharma Inc (TBPH) has a FCF Yield of 26.44%. This means that for every dollar of Theravance Biopharma Inc’s market capitalization, the company generates 26.44 cents in free cash flow.

What is the current Forward P/E ratio for Theravance Biopharma Inc (TBPH) as of Dec 16 2025?

As of Dec 16 2025, Theravance Biopharma Inc (TBPH) has a Forward P/E ratio of 25.07. This means the market is willing to pay $25.07 for every dollar of Theravance Biopharma Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Theravance Biopharma Inc (TBPH) as of Dec 16 2025?

As of Dec 16 2025, Theravance Biopharma Inc (TBPH) has a Forward P/S ratio of 8.27. This means the market is valuing TBPH at $8.27 for every dollar of expected revenue over the next 12 months.

TBPH Valuation